Table 4.
Anti‐viral resistance, cross resistance and recommended therapy
| NA‐based resistance | Common mutation sites | Resistance rates | Recommended therapy |
|---|---|---|---|
| LAM | M204V/I/S, L180M/I, M204V/I/S, A181T/V | 74% at 5 years | Switch to TDF |
| ADV | A181T/V, N236T, I233V | 29% at 3 years | Switch to TDF |
| LdT | M204I/V, rtA81T/V, rtL229W/V | 21.6% at 2 years | Switch to TDF |
| ETV | M204V/I, L180M, M250V, I169T | 1.2% at 6 years | Switch to TDF |
| TDF | No known mutation | 0% at 8 years | Continue TDF |
| LAM+ADV | A181V and N236T | Variable | Switch to TDF |
| Multiple resistance | Variable combination | Variable | Switch to TDF + ETV |
LAM, lamivudine; ADV, adefovir, LdT, telbivudine; ETV, entecavir; TDF, tenofovir.